- Home
- IQ vs ATAI Comparison
IQ vs ATAI Comparison
Compare IQ & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IQ | ATAI |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IQ | ATAI |
|---|---|---|
| Price | $1.23 | $3.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $2.91 | ★ $15.57 |
| AVG Volume (30 Days) | ★ 11.2M | 4.7M |
| Earning Date | 02-26-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,000.00 |
| Revenue This Year | $0.45 | N/A |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $1.15 |
| 52 Week High | $2.76 | $6.73 |
Technical Indicators
Market Signals| Indicator | IQ | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 22.96 | 40.11 |
| Support Level | N/A | $3.06 |
| Resistance Level | $2.16 | $4.30 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 15.63 | 12.69 |
Price Performance
Historical ComparisonAbout IQ iQIYI Inc.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.